<html>
  <head></head>
  <body>
    <div id="title">
      <h2>"Point in Time" Regulation Content</h2>
      <h4>
        <em> Pharmacy Operations and Drug Scheduling Act </em>
      </h4>
      <h3 style="line-height: 110%">Drug Schedules Regulation</h3>
      <h3>B.C. Reg. 9/98</h3>
    </div>
    <table cellpadding="3" cellspacing="0" class="tablestyle3">
      <tbody>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">Ambrisentan</td>
        </tr>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">Dabigatran and its salts and derivatives</td>
        </tr>
        <tr>
          <td align="right" valign="top">3</td>
          <td valign="top">
            Diphenhydramine and its salts and preparations (except for
            parenteral use or for topical use in concentrations of 2% or less
            when sold in containers of 300 mg or less of diphenhydramine
            hydrochloride)
          </td>
        </tr>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">Etravirine and its salts</td>
        </tr>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">
            Fluconazole (except when sold in a concentration of 150 mg per oral
            dosage unit as a single dose treatment and indicated for the
            treatment of vaginal candidiasis)
          </td>
        </tr>
        <tr>
          <td align="right" valign="top">3</td>
          <td valign="top">
            Fluconazole (when sold in a concentration of 150 mg per oral dosage
            unit and indicated for the treatment of vaginal candidiasis, in
            package sizes containing no more than 150 mg of fluconazole)
          </td>
        </tr>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">Methoxy polyethylene glycol-epoetin beta</td>
        </tr>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">Naltrexone and its salts and derivatives</td>
        </tr>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">Nelarabine</td>
        </tr>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">Nepafenac</td>
        </tr>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">Nilotinib and its salts</td>
        </tr>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">Panitumumab</td>
        </tr>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">Retapamulin</td>
        </tr>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">Rivaroxaban</td>
        </tr>
        <tr>
          <td align="right" valign="top">1</td>
          <td valign="top">Sitagliptin and its salts</td>
        </tr>
        <tr>
          <td align="right" valign="top">2</td>
          <td valign="top">
            Sodium picosulphate for oral purgatives, 10 mg per pack (when found
            in preparations with magnesium oxide 3.5 g and citric acid 12 g)
          </td>
        </tr>
      </tbody>
    </table>
  </body>
</html>
